[go: up one dir, main page]

GT199800058A - Derivados de nicotinamida. - Google Patents

Derivados de nicotinamida.

Info

Publication number
GT199800058A
GT199800058A GT199800058A GT199800058A GT199800058A GT 199800058 A GT199800058 A GT 199800058A GT 199800058 A GT199800058 A GT 199800058A GT 199800058 A GT199800058 A GT 199800058A GT 199800058 A GT199800058 A GT 199800058A
Authority
GT
Guatemala
Prior art keywords
nicotinamide derivatives
rheumatoids
pde4
inflammatories
phosphodiesterase
Prior art date
Application number
GT199800058A
Other languages
English (en)
Inventor
Anthony Marfat
Robert James Chambers
John Wesley Watson
John Bing Cheng
Allen Jacob Duplantier
Edward Fox Kleinman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199800058A publication Critical patent/GT199800058A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A DERIVADOS DE NICOTINAMIDA QUE SON INHIBIDORES SELECTIVOS DE LA FOSFODIESTERASA DE TIPO 4 (PDE4) Y DE LA PRODUCCION DEL FACTOR DE NECROSIS TUMORAL (TNF) Y QUE, COMO TALES, SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS RESPIRATORIOS, ALERGICOS, REUMATOIDES, DE REGULACION DEL PESO CORPORAL, INFLAMATORIOS Y DEL SISTEMA NERVIOSO CENTRAL. ESTOS COMPUESTOS TIENEN LA ESTRUCTURA QUIMICA (I), EN LA QUE A, B, D, E, R1, R2, R3, R4, R5, R6, R7 Y R8 SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE.
GT199800058A 1997-04-04 1998-04-03 Derivados de nicotinamida. GT199800058A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4340397P 1997-04-04 1997-04-04

Publications (1)

Publication Number Publication Date
GT199800058A true GT199800058A (es) 1999-09-25

Family

ID=21927000

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199800058A GT199800058A (es) 1997-04-04 1998-04-03 Derivados de nicotinamida.

Country Status (37)

Country Link
US (1) US6380218B1 (es)
EP (1) EP0971894A1 (es)
JP (2) JP2000510481A (es)
KR (1) KR20010005954A (es)
CN (1) CN1254335A (es)
AP (1) AP1388A (es)
AR (1) AR012574A1 (es)
AU (1) AU738037B2 (es)
BG (1) BG64356B1 (es)
BR (1) BR9810733A (es)
CA (1) CA2285548C (es)
CO (1) CO4950625A1 (es)
DZ (1) DZ2457A1 (es)
EA (1) EA003528B1 (es)
GT (1) GT199800058A (es)
HN (1) HN1998000057A (es)
HR (1) HRP980181B1 (es)
HU (1) HUP0001243A3 (es)
ID (1) ID22781A (es)
IL (1) IL132033A0 (es)
IS (1) IS5197A (es)
MA (1) MA26479A1 (es)
MY (1) MY141513A (es)
NO (1) NO314182B1 (es)
NZ (1) NZ337698A (es)
OA (1) OA11163A (es)
PA (1) PA8449601A1 (es)
PE (1) PE73299A1 (es)
PL (1) PL336148A1 (es)
SK (1) SK132899A3 (es)
TN (1) TNSN98045A1 (es)
TR (2) TR199902432T2 (es)
TW (1) TW519539B (es)
UA (1) UA67737C2 (es)
WO (1) WO1998045268A1 (es)
YU (1) YU49899A (es)
ZA (1) ZA982853B (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
RU2235095C2 (ru) 1998-10-06 2004-08-27 Дайниппон Фармасьютикал Ко., Лтд. 2,3-дизамещенное производное пиридина, способы его получения, содержащая его фармацевтическая композиция и промежуточный продукт для его получения
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US6620841B1 (en) 1998-12-25 2003-09-16 Shionogi & Co., Ltd. Aromatic heterocycle compounds having HIV integrase inhibiting activities
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
CZ302882B6 (cs) 1999-08-21 2012-01-04 Nycomed Gmbh Farmaceutický prostredek
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
KR20020072299A (ko) 2000-01-31 2002-09-14 화이자 프로덕츠 인코포레이티드 Ｐｄｅ4 이소자임의 선택적 억제제로서 유용한니코틴아미드 벤조접합된-헤테로사이클릴 유도체
WO2001057025A1 (en) 2000-01-31 2001-08-09 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
NL1015313C2 (nl) 2000-05-26 2001-11-27 Dsm Nv Werkwijze voor de bereiding van enantiomeer verrijkte esters en alcoholen.
HUP0301713A3 (en) * 2000-06-13 2005-04-28 Shionogi & Co Pharmaceutical compositions containing propenone derivatives and their use
EP1309595A2 (en) * 2000-08-09 2003-05-14 Boehringer Ingelheim Pharmaceuticals Inc. Synthesis of (r)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-h-imidazo(1,2-a) imidazol-2-one
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
WO2002060896A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
CA2436551A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
ES2239203T3 (es) * 2001-01-31 2005-09-16 Pfizer Products Inc. Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4.
PL364135A1 (en) 2001-01-31 2004-12-13 Pfizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
ES2706902T3 (es) 2001-06-26 2019-04-01 Amgen Inc Anticuerpos para OPGL
ES2400070T3 (es) * 2001-12-03 2013-04-05 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
OA12768A (en) * 2002-02-11 2006-07-04 Pfizer Nicotinamide derivatives useful as PDE4 inhibitors.
AU2003201745A1 (en) * 2002-02-11 2003-09-04 Pfizer Limited Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
GB0203193D0 (en) * 2002-02-11 2002-03-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CA2481178A1 (en) * 2002-04-02 2003-10-23 Tatsuhiro Obata Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative
US20040076668A1 (en) * 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
GB0302094D0 (en) * 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
NZ577553A (en) * 2003-02-21 2011-01-28 Resmed Ltd Nasal assembly
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
BRPI0409229A (pt) 2003-04-01 2006-03-28 Applied Research Systems inibidores das fosfodiesterases na infertilidade
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
US20050186276A1 (en) * 2003-07-17 2005-08-25 Pfizer Inc Pharmaceutical formulations
HRP20060073B1 (hr) * 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
GB0317484D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US7132435B2 (en) * 2003-07-25 2006-11-07 Pfizer Inc. Compounds
US20050020587A1 (en) * 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
GB0317472D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
GB0317509D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0317516D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0317498D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Compounds
GB0317471D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Novel compounds
CA2536870C (en) * 2003-09-03 2009-10-27 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
EP1669348A4 (en) * 2003-09-30 2009-03-11 Eisai R&D Man Co Ltd NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20050241110A1 (en) * 2004-04-09 2005-11-03 Bruce Baker Ergonomic handles, especially for garden tools
CN101010315A (zh) * 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
CN1950333A (zh) 2004-05-04 2007-04-18 辉瑞大药厂 取代的甲基芳基或杂芳基酰胺化合物
EP1742627A4 (en) 2004-05-06 2009-08-26 Plexxikon Inc PDE4B HEMMER AND ITS USE
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
US20090227799A1 (en) * 2004-08-09 2009-09-10 Kazutaka Nakamoto Novel Antimalarial Agent Containing Heterocyclic Compound
CN101048407A (zh) 2004-09-03 2007-10-03 普莱希科公司 双环杂芳基pde4b抑制剂
US8597947B2 (en) 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
WO2006070370A2 (en) * 2004-12-29 2006-07-06 Hadasit Medical Research Services & Development Limited Stem cells culture systems
WO2006077497A1 (en) * 2005-01-21 2006-07-27 Pfizer Limited Crystalline forms cis-5-fluoro-n-[4-(2-hydroxy-4-methylbenzamido) cyclohexyl]-2-(tetrahydrothiopyran-a-yloxy) nicotinamide
CA2598531A1 (en) * 2005-02-24 2006-08-31 Merck & Co., Inc. Benzazole potentiators of metabotropic glutamate receptors
JP4874958B2 (ja) * 2005-03-30 2012-02-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジン誘導体を含有する抗真菌剤
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
TWI385169B (zh) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
EP1946840B1 (en) * 2005-11-04 2019-08-21 NGK Insulators, Ltd. Honeycomb structure and honeycomb catalyst
ES2418153T3 (es) * 2006-03-08 2013-08-12 Cortria Corporation Terapia de combinación con inhibidores no selectivos de COX para prevenir lesiones gástricas relacionadas con COX
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
US8183264B2 (en) * 2006-09-21 2012-05-22 Eisai R&D Managment Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
TW200841879A (en) * 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
AU2008246798A1 (en) * 2007-04-27 2008-11-13 Eisai R&D Management Co., Ltd. Salt of heterocycle-substituted pyridine derivative or crystal thereof
DE102007042754A1 (de) 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
US8153651B2 (en) * 2007-11-13 2012-04-10 Evotec Ag Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
AU2009244395A1 (en) * 2008-05-06 2009-11-12 Cortria Corporation 1-methylnicotinamide analogs
CN102137669A (zh) * 2008-06-03 2011-07-27 弗雷森纽斯医疗护理德国有限责任公司 包含γ分泌酶调节剂的药物组合物
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
SG178948A1 (en) 2009-09-01 2012-04-27 Catabasis Pharmaceuticals Inc Fatty acid niacin conjugates and their uses
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
AU2011208357A1 (en) * 2010-01-25 2012-08-09 Kareus Therapeutics Sa Novel compositions for reducing Abeta 42 production and their use in treating Alzheimer's Disease (AD)
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
JP2013076691A (ja) * 2011-09-12 2013-04-25 Taisho Pharmaceutical Co Ltd 疲労バイオマーカー
EP2759533B1 (en) * 2011-09-22 2017-08-02 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
KR102226587B1 (ko) * 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
BR112016030690B1 (pt) 2014-06-27 2023-11-14 Nogra Pharma Limited Compostos moduladores do receptor de arila, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN108530301B (zh) * 2018-06-04 2020-11-20 上海吉奉生物科技有限公司 一种2,4,6-三氟苄胺的合成方法
CN116270639B (zh) * 2023-03-31 2025-08-22 中山大学 N-(2-(5-(1，2-二硫戊环-3-基)戊酰胺基)乙基)烟酰胺的新应用
WO2025143305A1 (ko) * 2023-12-28 2025-07-03 (주)앰틱스바이오 아미노 니코틴아마이드 구조를 포함하는 유도체 화합물 및 이를 포함하는 항진균성 약학적 조성물
WO2025143877A1 (ko) * 2023-12-28 2025-07-03 (주)앰틱스바이오 아미노 니코틴아마이드 구조를 포함하는 유도체 화합물 및 이를 포함하는 항진균성 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2140772A5 (en) * 1971-06-07 1973-01-19 Aries Robert Phenoxynicotinoylaminophenols - analgesics tranquillisers antipyretics, anti-inflammatories and antirheumatics
FR2197872A1 (en) * 1972-09-04 1974-03-29 Dynachim Sarl 2-Phenoxy nicotinic esters and amides - prepd. by reaction of nicotinic acid anhydride or halide with an alcohol or amine
DE2706977A1 (de) * 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
DE2720926C2 (de) * 1977-05-10 1983-02-17 Hoechst Ag, 6000 Frankfurt Benzolsulfonylharnstoffe und Verfahren zu ihrer Herstellung
US4251263A (en) * 1979-09-04 1981-02-17 Stauffer Chemical Company N-substituted, 2-phenoxynicotinamide compounds and the herbicidal use thereof
US4270946A (en) * 1979-10-01 1981-06-02 Stauffer Chemical Company N-Aryl,2-phenoxy nicotinamide compounds and the herbicidal use thereof
IL64220A (en) * 1980-11-21 1985-06-30 May & Baker Ltd Nicotinamide derivatives,their preparation and their use as herbicides
US4692185A (en) * 1986-01-13 1987-09-08 Stauffer Chemical Company N-(ortho-substituted) benzyl, 3-trifluoromethylphenoxy nicotinamides as herbicides
US4861891A (en) * 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
FR2639185B1 (fr) * 1988-11-22 1991-01-25 Rhone Poulenc Agrochimie Produit herbicide, son utilisation et procede pour la lutte selective contre les mauvaises herbes dans les cultures de riz et de cereales
EP0500989B1 (en) * 1991-02-27 1998-12-09 Lacer, S.A. N-(alpha-substituted-pyridinyl) carbonyl dipeptide antihypertensive agents
DE4200323A1 (de) * 1992-01-09 1993-07-15 Bayer Ag Herbizide und pflanzennematizide mittel auf basis von mercaptonicotinsaeurederivaten
CA2139088A1 (en) * 1993-12-28 1995-06-29 Akihiko Ishida Indane derivatives, processes for preparing the same and synthetic intermediate of the same
JP3406689B2 (ja) * 1994-03-15 2003-05-12 株式会社大塚製薬工場 ナフチリジン及びピリドピラジン誘導体
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use

Also Published As

Publication number Publication date
BR9810733A (pt) 2000-09-12
TW519539B (en) 2003-02-01
YU49899A (sh) 2002-09-19
MY141513A (en) 2010-05-14
JP2004083583A (ja) 2004-03-18
CA2285548C (en) 2006-07-11
HUP0001243A3 (en) 2000-10-30
OA11163A (en) 2003-04-28
HRP980181B1 (en) 2003-06-30
HUP0001243A2 (hu) 2000-09-28
WO1998045268A1 (en) 1998-10-15
ZA982853B (en) 1999-11-24
TR199902432T2 (xx) 2000-01-21
IL132033A0 (en) 2001-03-19
UA67737C2 (uk) 2004-07-15
MA26479A1 (fr) 2004-12-20
EA003528B1 (ru) 2003-06-26
TNSN98045A1 (fr) 2005-03-15
AP9801218A0 (en) 1998-06-30
JP2000510481A (ja) 2000-08-15
AR012574A1 (es) 2000-11-08
ID22781A (id) 1999-12-09
PA8449601A1 (es) 2000-05-24
BG64356B1 (bg) 2004-11-30
HRP980181A2 (en) 1999-02-28
CA2285548A1 (en) 1998-10-15
CO4950625A1 (es) 2000-09-01
NO314182B1 (no) 2003-02-10
SK132899A3 (en) 2000-09-12
EA199900787A1 (ru) 2000-04-24
AP1388A (en) 2005-04-14
AU738037B2 (en) 2001-09-06
IS5197A (is) 1999-09-24
BG103725A (en) 2000-07-31
TR200001847T2 (tr) 2002-06-21
EP0971894A1 (en) 2000-01-19
DZ2457A1 (fr) 2004-11-08
HN1998000057A (es) 1999-01-08
NO994791D0 (no) 1999-10-01
KR20010005954A (ko) 2001-01-15
PL336148A1 (en) 2000-06-05
PE73299A1 (es) 1999-08-10
NZ337698A (en) 2001-07-27
CN1254335A (zh) 2000-05-24
US6380218B1 (en) 2002-04-30
NO994791L (no) 1999-12-01
AU6227398A (en) 1998-10-30

Similar Documents

Publication Publication Date Title
GT199800058A (es) Derivados de nicotinamida.
HN1999000130A (es) 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas.
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
GT199800200A (es) Compuestos azapoliciclicos condensados con arilo.
SV2002000289A (es) Antagonistas del factor liberador de la corticotropina ref. pc10759/20117/bb
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
UY26231A1 (es) Compuestos de indazol y composiciones farmaceuticas para la inhibicion de proteina kinasa y metodo para su uso. bajo ley 17.164
ES2154683T3 (es) Indoles sustituidos como inhibidores de fosfodiesterasa de tipo iv.
GT199800021A (es) Utilizacion de antagonistas de los receptores de canabinoides centrales para la preparacion de medicamentos.
ATE377592T1 (de) Neurotropische substituierte pyrimidine
NO20074961L (no) Imidazopyridazinforbindelser
ES2051796T3 (es) Procedimiento para preparar derivados de dihidrobenzopiran-2-carboxilatos alcoxi-sustituidos.
BR0116001A (pt) Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda
ATE412415T1 (de) Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
DE60025604D1 (de) Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
GT199800032A (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas.
EA200701296A1 (ru) 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства
DE69807587D1 (de) Quinazolin-4-on AMPA Antagonisten
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
AR031200A1 (es) Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
ES2171134A1 (es) Procedimiento para la preparacion del pompuesto 2-(3,5-bis-trifluorometil-fenil)-n-,etil-n-(6-morfolin-4-il-o-tolil-priridin-3-il)-isobutiramida. el producto per se, y su uso para la preparacion de medicamentos.
BRPI0412809A (pt) compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6
YU75803A (sh) Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja